Diligence memo · auto-generated · as of July 2, 2026
Viela Bio, Inc.
Viela Bio, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Viela Bio, Inc. operates in Biotechnology, based in GAITHERSBURG.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Viela Bio, Inc. has raised $357M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $282M on 2018-02-23.
Most recent recorded round closed around 2019-06-12.
Valuation (modeled)modeled
Provath models Viela Bio, Inc. at approximately $3.1B (range $340M–$6.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.73× the median modeled value of Series D+ Biotechnology companies in 2019–2021 (58 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 7.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Sarepta Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., Affinivax, Inc., Sonoma Biotherapeutics, Inc., Instil Bio, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.